Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110014/S013

MarginProbe

Dilon Medical Technologies, Ltd. · Decision date Sep 17, 2025

FDA DECISIONP110014/S013

What did the FDA approve?

FDA records P110014/S013 as a supplement to PMA P110014, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Sep 17, 2025.

FDA approval order statement

Approval for the modification of the MP 2.0 System including MP 2.0 Console and MP 2.a Probe with the use of multiple array technology with multiple sensors.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
General, Plastic Surgery
Decision date
Sep 17, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P110014/S013
Regulatory pathway
PMA supplement
Product code
OEE
Decision code
APPR
Decision date
Sep 17, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Diagnostic low electric field.

Product code
OEE
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P110014/S013 received

    Application receipt date recorded by FDA.

  2. P110014/S013 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P110014. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Dilon Medical Technologies, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
20 Alon Hatavor St., P.O. Box 3131, Business Park-South 3088900

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records